跳至主要内容
临床试验/ACTRN12610000558022
ACTRN12610000558022进行中(未招募)未知

A prospective non-interventional study to evaluate the effect of Triptorelin Embonate (Diphereline (TM) 11.25mg) on lower urinary tract symptoms (LUTS) in Australian prostate cancer patients.

Ipsen Pty Ltd0 个研究点目标入组 70 人开始时间: 2010年7月12日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
Ipsen Pty Ltd
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
Male

入选标准

  • 1.The patient is suffering from locally-advanced (at least Tumour 3 stage) or metastatic prostate cancer scheduled to receive Diphereline (TM) 11.25mg.
  • 2.The patient is presenting with moderate to severe LUTS ((lower urinary tract symptoms) IPSS score >7).

排除标准

  • 1.The patient has a risk of serious complication in the case of tumour flare (vertbral metastases threatening spinal cord compression or significant obstructive uropathy).
  • 2.History of surgical castration.
  • 3.History of urethral stricture.
  • 4.Life expectancy of less than 12 months.
  • 5.Has undergone surgery for the treatment of lower urinary tract symptoms(LUTS).
  • 6.Therapy with a Luteinizing hormone-releasing hormone (LHRH) analogue in the last 6 months.
  • 7. Has received alpha receptor blockers in the last two weeks prior to the start of the study.

研究者

发起方
Ipsen Pty Ltd

相似试验